World Library  
Flag as Inappropriate
Email this Article

Pargyline

Article Id: WHEBN0007530849
Reproduction Date:

Title: Pargyline  
Author: World Heritage Encyclopedia
Language: English
Subject: Clorgiline, Deserpidine, Lazabemide, Talipexole, Safinamide
Collection: Alkynes, Amines, Antihypertensive Agents, Aromatic Compounds, Monoamine Oxidase Inhibitors
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Pargyline

Pargyline
Skeletal formula of pargyline
Ball-and-stick model of the pargyline molecule
Systematic (IUPAC) name
N-Benzyl-N-methylprop-2-yn-1-amine
Clinical data
MedlinePlus
Identifiers
CAS Registry Number  Y
ATC code C02 C02
PubChem CID:
IUPHAR/BPS
DrugBank  N
ChemSpider  Y
UNII  Y
ChEMBL  Y
Chemical data
Formula C11H13N
Molecular mass 159.23 g/mol
 N   

Pargyline (Eutonyl) is an irreversible selective monoamine oxidase (MAO) inhibitor drug (IC50 for MAO-A is 0.01152micromol/L and for MAO-B is 0.00820micromol/L.) [1] [2] It was brought to market in the US and the UK by Abbott in 1963 as "Eutonyl" as an antidepressant, and was one of several other MAO inhibitors brought to market in the 1960s, along with nialamide, isocarboxazid, phenelzine, and tranylcypromine.[3]:146[4]:60[5]

As of 2007 the drug was discontinued[6] and as of 2014 there were no generic versions in the US.[7]

See also

References

  1. ^ Fisar Z, Hroudová J, Raboch J. (2010). "Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers.". Neuro Endocrinol Lett. 31 (5): 645–56.  
  2. ^ Murphy DL, Karoum F, Pickar D, et al. (1998). "Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline)". J. Neural Transm. Suppl. 52: 39–48.  
  3. ^ Edward Shorter, A historical dictionary of psychiatry. Oxford University Press, Inc 2005. ISBN 0195176685
  4. ^ William M. Wardell and Louis Lasagna. Regulation Drug Development (Evaluative Studies 21) American Enterprise Institute (1975) ISBN 0844731676
  5. ^ Council on Drugs New Drugs and Developments in Therapeutics: Pargyline Hydrochloride (Eutonyl) JAMA. 1963;184(11):887. doi:10.1001/jama.1963.03700240079013.
  6. ^ W. Steven Pray Interactions Between Nonprescription Products and Psychotropic Medications US Pharmacist. 2007;32(11):12-15.
  7. ^ FDA Eutonyl in the Drugs@FDA Database Accessed July 19, 2014



This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.